Clinical trial
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell…
NCT00030641 · Genta Incorporated, Industry · Unknown status
Key facts
| NCT number | NCT00030641 |
|---|---|
| Title | Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer |
| Official title | Randomized Study of Docetaxel Versus Docetaxel Plus Genasense™ (G3139; Bcl-2 Antisense Oligonucleotide) in Patients With Previously Treated Non-Small Cell Lung Cancer |
| Lead sponsor | Genta Incorporated, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | oblimersen sodium, docetaxel |
| Start date | Oct 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 6, 2014 |
| Countries | Canada, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: